Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.01 – $0.05
24% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $678.0K | $871.5K | $762.0K | $1.0M | $1.0M | $2.2M | $2.9M | $1.4M |
| Cost of revenue | $155.0K | $1.5M | $165.0K | $302.0K | $428.0K | $2.6M | $1.1M | $6.1M |
| Gross profit | $523.0K | −$678.0K | $597.0K | $711.0K | $613.0K | −$408.0K | $1.8M | −$4.8M |
| Gross margin | 77.1% | -77.8% | 78.3% | 70.2% | 58.9% | -18.7% | 62.2% | -354.6% |
| R&D | $2.1M | $9.0M | $7.9M | $8.5M | $10.8M | $9.5M | $1.8M | $0 |
| Operating income | −$10.9M | −$13.1M | −$13.7M | −$17.2M | −$24.2M | −$21.8M | −$15.1M | −$20.2M |
| EBITDA | −$9.8M | −$11.3M | −$12.2M | −$15.7M | −$24.4M | −$19.0M | −$13.0M | −$14.6M |
| Net income | −$8.9M | −$11.3M | −$11.6M | −$15.0M | −$21.7M | −$20.1M | −$14.2M | −$19.5M |
| Net margin | -1318.9% | -1300.5% | -1523.1% | -1481.9% | -2083.2% | -921.0% | -497.0% | -1444.0% |
| EPS (diluted) | -0.07 | -0.07 | -0.07 | -0.07 | -0.09 | -0.08 | -0.05 | -0.06 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $2M | $-0.00 | $-0.01–$0.00 | 1 |
| 2027 | $5M | $-0.00 | $-0.01–$0.00 | 1 |
| 2028 | $8M | $-0.00 | $-0.00–$0.00 | 1 |
Forward consensus · source: Financial Modeling Prep
CELLBXHEALTH PLC
No one on the platform currently holds ANPCF.
No tracked institution reports a position in ANPCF as of their last filing.
No one on the platform has traded ANPCF yet.
| $13M |
| — |
| NGMDFNuGen Medical Devices Inc. | $0.02 | +0.00% | $4M | — |
| NSVGFNass Valley Gateway Ltd. | $0.01 | +0.00% | $3M | — |
Source: Financial Modeling Prep · peers by sector/industry
Trading at 2.1× sales vs its 21.8× historical median P/S.
Fair value ≈ $0.20 · price $0.02 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.